Skip to main content


Concurrent with a rise in opioid overdose deaths, fewer new patients received buprenorphine prescriptions for the treatment of opioid use disorder during the early months of the COVID-19 pandemic, according to researchers at Princeton University.
The Foundation for Opioid Response Efforts is providing $1.3 million in grants for six organizations to assess temporary regulatory relaxations and policy changes that were enacted to ease access to treatment for opioid use disorder without in-person interactions in response to the COVID-19 pandemic.
As the next wave of the COVID-19 pandemic arrives, it’s crucial for providers to enact staff rounding programs to understand the evolving concerns of their employees.
While providers wait for vaccines to slow the COVID-19 pandemic and better treatments to reduce the death toll among those infected, there are steps that can be taken to help address the “other” surge—in the opioid crisis.
An increase in demand for treatment services and stockpiles of dollars for private equity investors who are itching to spend could spark a hotbed of M&A activity in the behavioral health sector, particularly for substance use disorder treatment providers, Braff Group president Dexter Braff told TCIV attendees.
Back to Top